Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

Transaction will add FDA Breakthrough Device-Designated technology with active U.S. pivotal IDE trial, positioning Galmed to address one of colorectal surgery’s most serious unmet needs.
Colospan’s CG-100 Intraluminal Bypass Device, is CE marked under EU’s Medical Device Regulation (“MDR”) and ready for commercial launch in the EU and Israel. Galmed contemplates an investment of $6 million to launch Colospan’s device during H2 2026 in Europe with an initial focus on Germany, Austria and Switzerland.
Upon closing, Colospan will become a wholly owned subsidiary of Galmed, repositioning it as a GI-focused medtech and biopharmaceutical platform. Transaction approved by both boards; expected to close Q2 2026.